Literature DB >> 25961922

p38γ MAPK is required for inflammation-associated colon tumorigenesis.

N Yin1, X Qi1, S Tsai2, Y Lu3, Z Basir4, K Oshima4, J P Thomas5, C R Myers1, G Stoner5, G Chen1,6.   

Abstract

Chronic inflammation has long been considered to causatively link to colon cancer development. However, signal transduction pathways involved remain largely unidentified. Here, we report that p38γ mitogen-activated protein kinase mediates inflammatory signaling to promote colon tumorigenesis. Inflammation activates p38γ in mouse colon tissues and intestinal epithelial cell-specific p38γ knockout (KO) attenuates colitis and inhibits pro-inflammatory cytokine expression. Significantly, p38γ KO inhibits tumorigenesis in a colitis-associated mouse model. The specific p38γ pharmacological inhibitor pirfenidone also suppresses pro-inflammatory cytokine expression and colon tumorigenesis. The tumor-promoting activity of epithelial p38γ was further demonstrated by xenograft studies. In addition, p38γ is required for β-catenin/Wnt activities and p38γ stimulates Wnt transcription by phosphorylating β-catenin at Ser605. These results show that p38γ activation links inflammation and colon tumorigenesis. Targeting p38γ may be a novel strategy for colon cancer prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25961922     DOI: 10.1038/onc.2015.158

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

1.  Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development.

Authors:  R H Adams; A Porras; G Alonso; M Jones; K Vintersten; S Panelli; A Valladares; L Perez; R Klein; A R Nebreda
Journal:  Mol Cell       Date:  2000-07       Impact factor: 17.970

Review 2.  Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update.

Authors:  John M Kyriakis; Joseph Avruch
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

3.  Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice.

Authors:  Rikako Suzuki; Hiroyuki Kohno; Shigeyuki Sugie; Hitoshi Nakagama; Takuji Tanaka
Journal:  Carcinogenesis       Date:  2005-08-04       Impact factor: 4.944

4.  Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells.

Authors:  T Abdollahi; N M Robertson; A Abdollahi; G Litwack
Journal:  Apoptosis       Date:  2005-12       Impact factor: 4.677

5.  p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion.

Authors:  Xiaomei Qi; Jun Tang; Mathew Loesch; Nicole Pohl; Serhan Alkan; Guan Chen
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

6.  β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.

Authors:  Stephan P Tenbaum; Paloma Ordóñez-Morán; Isabel Puig; Irene Chicote; Oriol Arqués; Stefania Landolfi; Yolanda Fernández; José Raúl Herance; Juan D Gispert; Leire Mendizabal; Susana Aguilar; Santiago Ramón y Cajal; Simó Schwartz; Ana Vivancos; Eloy Espín; Santiago Rojas; José Baselga; Josep Tabernero; Alberto Muñoz; Héctor G Palmer
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

7.  p38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9.

Authors:  Mathew Loesch; Hui-Ying Zhi; Song-Wang Hou; Xiao-Mei Qi; Rong-Shan Li; Zainab Basir; Thomas Iftner; Ana Cuenda; Guan Chen
Journal:  J Biol Chem       Date:  2010-03-15       Impact factor: 5.157

8.  Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-κB.

Authors:  Ye Tian; Wen Yuan; Nobuyuki Fujita; Jianru Wang; Hua Wang; Irving M Shapiro; Makarand V Risbud
Journal:  Am J Pathol       Date:  2013-04-17       Impact factor: 4.307

9.  p38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor.

Authors:  Xiaomei Qi; Jun Tang; Rocky Pramanik; Richard M Schultz; Senji Shirasawa; Takehiko Sasazuki; Jiahuai Han; Guan Chen
Journal:  J Biol Chem       Date:  2004-03-22       Impact factor: 5.157

10.  Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Authors:  Stefan Schreiber; Brian Feagan; Geert D'Haens; Jean-Frederic Colombel; Karel Geboes; Mikhail Yurcov; Vasily Isakov; Oleg Golovenko; Charles N Bernstein; Diether Ludwig; Trevor Winter; Ulrich Meier; Chan Yong; Jürgen Steffgen
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

View more
  18 in total

1.  Diclofenac induced apoptosis via altering PI3K/Akt/MAPK signaling axis in HCT 116 more efficiently compared to SW480 colon cancer cells.

Authors:  Elif Damla Arisan; Zehragül Ergül; Gülnihal Bozdağ; Özge Rencüzoğulları; Ajda Çoker-Gürkan; Pınar Obakan-Yerlikaya; Deniz Coşkun; Narçin Palavan-Ünsal
Journal:  Mol Biol Rep       Date:  2018-11-08       Impact factor: 2.316

2.  The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation.

Authors:  Ning Yin; Adrienne Lepp; Yongsheng Ji; Matthew Mortensen; Songwang Hou; Xiao-Mei Qi; Charles R Myers; Guan Chen
Journal:  J Biol Chem       Date:  2017-07-24       Impact factor: 5.157

3.  Phenylpyrrolidine structural mimics of pirfenidone lacking antifibrotic activity: A new tool for mechanism of action studies.

Authors:  Andrew J Haak; Megan A Girtman; Mohamed F Ali; Eva M Carmona; Andrew H Limper; Daniel J Tschumperlin
Journal:  Eur J Pharmacol       Date:  2017-05-30       Impact factor: 4.432

Review 4.  Centrosome Dynamics and Its Role in Inflammatory Response and Metastatic Process.

Authors:  Massimo Pancione; Luigi Cerulo; Andrea Remo; Guido Giordano; Álvaro Gutierrez-Uzquiza; Paloma Bragado; Almudena Porras
Journal:  Biomolecules       Date:  2021-04-23

5.  p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis.

Authors:  Fang Wang; Xiao-Mei Qi; Ryan Wertz; Matthew Mortensen; Catherine Hagen; John Evans; Yuri Sheinin; Michael James; Pengyuan Liu; Susan Tsai; James Thomas; Alexander Mackinnon; Michael Dwinell; Charles R Myers; Ramon Bartrons Bach; Liwu Fu; Guan Chen
Journal:  Cancer Res       Date:  2020-06-24       Impact factor: 13.312

6.  GM1 Induced the inflammatory response related to the Raf-1/MEK1/2/ERK1/2 pathway in co-culture of pig mesenchymal stem cells with RAW264.7.

Authors:  Dong Hoon Kwak; You Na Seo; Ju Hyoung Lee; Soon Ju Park; Young Ho Cho; Ji-Su Kim; Sun-Uk Kim; Young-Kug Choo
Journal:  Anim Cells Syst (Seoul)       Date:  2018-03-22       Impact factor: 1.815

Review 7.  Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy.

Authors:  Xiao-Mei Qi; Fang Wang; Matthew Mortensen; Ryan Wertz; Guan Chen
Journal:  Acta Pharm Sin B       Date:  2018-05-22       Impact factor: 11.413

Review 8.  The p38 Pathway: From Biology to Cancer Therapy.

Authors:  Adrián Martínez-Limón; Manel Joaquin; María Caballero; Francesc Posas; Eulàlia de Nadal
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

9.  A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.

Authors:  Adi Nagler; David W Vredevoogd; Michal Alon; Phil F Cheng; Sophie Trabish; Shelly Kalaora; Rand Arafeh; Victoria Goldin; Mitchell P Levesque; Daniel S Peeper; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2019-10-10       Impact factor: 4.693

10.  Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma.

Authors:  Xu Hannah Zhang; Sangkil Nam; Jun Wu; Chih-Hong Chen; Xuxiang Liu; Hongzhi Li; Timothy McKeithan; Qiang Gong; Wing C Chan; Hongwei Holly Yin; Yate-Ching Yuan; Raju Pillai; Christiane Querfeld; David Horne; Yuan Chen; Steven T Rosen
Journal:  J Invest Dermatol       Date:  2018-07-14       Impact factor: 7.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.